Raji Balasubramanian1, Olga Demler2, Marta Guasch-Ferré3, Nina P Paynter2, Ryan Sheehan1, Simin Liu4,5, JoAnn E Manson2,4, Jordi Salas-Salvadó6,7,8, Miguel Á Martínez-Gonzalez3,8,9,10, Frank B Hu3,4, Clary Clish11, Kathryn M Rexrode12. 1. Department of Biostatistics & Epidemiology, University of Massachusetts-Amherst (R.B., R.S.). 2. Division of Preventive Medicine (O.D., J.P.P., J.E.M.), Brigham and Women's Hospital, Harvard Medical School. 3. Department of Nutrition (M.G.-F., M.A.M.-G., F.B.H.). 4. Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, MA (S.L., J.E.M., F.B.H.). 5. Departments of Epidemiology & Medicine, Brown University, Providence, RI (S.L.). 6. Universitat Rovira i Virgili, Departament de Bioquímica i Biotecnologia, Unitat de Nutrició Humana, Hospital Universitari San Joan de Reus (J.S.-S.). 7. Institut d'Investigació Pere Virgili (IISPV), Reus (J.S.-S.). 8. Consorcio CIBER, M.P. Fisiopatología de la Obesidad y Nutrición (CIBERObn), Instituto de Salud Carlos III (ISCIII), Madrid (J.S.-S., M.A.M.-G.). 9. Department of Preventive Medicine & Public Health, University of Navarra (M.A.M.-G.). 10. IdiSNA (Instituto de Investigación Sanitaria de Navarra), Pamplona, Spain (M.A.M.-G.). 11. Broad Institute of the Massachusetts Institute of Technology & Harvard University, Cambridge, MA (C.C.). 12. Division of Women's Health (K.M.R.), Brigham and Women's Hospital, Harvard Medical School.
Abstract
BACKGROUND: In the WHI-HT trials (Women's Health Initiative Hormone Therapy), treatment with oral conjugated equine estrogens and medroxyprogesterone acetate (CEE+MPA) resulted in increased risk of coronary heart disease (CHD), whereas oral conjugated equine estrogens (CEE) did not. METHODS: Four hundred eighty-one metabolites were measured at baseline and at 1-year in 503 and 431 participants in the WHI CEE and CEE+MPA trials, respectively. The effects of randomized HT on the metabolite profiles at 1-year was evaluated in linear models adjusting for baseline metabolite levels, age, body mass index, race, incident CHD, prevalent hypertension, and diabetes. Metabolites with discordant effects by HT type were evaluated for association with incident CHD in 944 participants (472 CHD cases) in the WHI-OS (Women's Health Initiative Observational Study), with replication in an independent cohort of 980 men and women at high risk for cardiovascular disease. RESULTS: HT effects on the metabolome were profound; 62% of metabolites significantly changed with randomized CEE and 52% with CEE+MPA (false discovery rate-adjusted P value<0.05) in multivariable models. Concerted increases in abundance were seen within various metabolite classes including triacylglycerols, phosphatidylethanolamines, and phosphatidylcholines; decreases in abundance was observed for acylcarnitines, lysophosphatidylcholines, quaternary amines, and cholesteryl/cholesteryl esters. Twelve metabolites had discordant effects by HT type and were associated with incident CHD in the WHI-OS; a metabolite score estimated in a Least Absolute Shrinkage and Selection Operator regression was associated with CHD risk with an odds ratio of 1.47 per SD increase (95% CI, 1.27-1.70, P<10-6). All twelve metabolites were altered in the CHD protective direction by CEE treatment. One metabolite (lysine) was significantly altered in the direction of increased CHD risk by CEE+MPA; the remaining 11 metabolites were not significantly changed by CEE+MPA. The CHD associations of a subset of 4 metabolites including C58:11 triacylglycerol, C54:9 triacylglycerol, C36:1 phosphatidylcholine and sucrose replicated in an independent dataset of 980 participants in the PREDIMED trial (Prevención con Dieta Mediterránea). CONCLUSIONS: Randomized treatment with oral HT resulted in large metabolome shifts that generally favored CEE alone over CEE+MPA in term of CHD risk. Discordant metabolite effects between HT regimens may partially mediate the differences in CHD risk between the 2 WHI-HT trials.
BACKGROUND: In the WHI-HT trials (Women's Health Initiative Hormone Therapy), treatment with oral conjugated equine estrogens and medroxyprogesterone acetate (CEE+MPA) resulted in increased risk of coronary heart disease (CHD), whereas oral conjugated equine estrogens (CEE) did not. METHODS: Four hundred eighty-one metabolites were measured at baseline and at 1-year in 503 and 431 participants in the WHI CEE and CEE+MPA trials, respectively. The effects of randomized HT on the metabolite profiles at 1-year was evaluated in linear models adjusting for baseline metabolite levels, age, body mass index, race, incident CHD, prevalent hypertension, and diabetes. Metabolites with discordant effects by HT type were evaluated for association with incident CHD in 944 participants (472 CHD cases) in the WHI-OS (Women's Health Initiative Observational Study), with replication in an independent cohort of 980 men and women at high risk for cardiovascular disease. RESULTS: HT effects on the metabolome were profound; 62% of metabolites significantly changed with randomized CEE and 52% with CEE+MPA (false discovery rate-adjusted P value<0.05) in multivariable models. Concerted increases in abundance were seen within various metabolite classes including triacylglycerols, phosphatidylethanolamines, and phosphatidylcholines; decreases in abundance was observed for acylcarnitines, lysophosphatidylcholines, quaternary amines, and cholesteryl/cholesteryl esters. Twelve metabolites had discordant effects by HT type and were associated with incident CHD in the WHI-OS; a metabolite score estimated in a Least Absolute Shrinkage and Selection Operator regression was associated with CHD risk with an odds ratio of 1.47 per SD increase (95% CI, 1.27-1.70, P<10-6). All twelve metabolites were altered in the CHD protective direction by CEE treatment. One metabolite (lysine) was significantly altered in the direction of increased CHD risk by CEE+MPA; the remaining 11 metabolites were not significantly changed by CEE+MPA. The CHD associations of a subset of 4 metabolites including C58:11 triacylglycerol, C54:9 triacylglycerol, C36:1 phosphatidylcholine and sucrose replicated in an independent dataset of 980 participants in the PREDIMED trial (Prevención con Dieta Mediterránea). CONCLUSIONS: Randomized treatment with oral HT resulted in large metabolome shifts that generally favored CEE alone over CEE+MPA in term of CHD risk. Discordant metabolite effects between HT regimens may partially mediate the differences in CHD risk between the 2 WHI-HT trials.
Entities:
Keywords:
cardiovascular disease; estrogens; heart disease; medroxyprogesterone acetate; metabolome; women
Authors: Ashish Yeri; Rachel A Murphy; Megan M Marron; Clary Clish; Tamara B Harris; Gregory D Lewis; Anne B Newman; Venkatesh L Murthy; Ravi V Shah Journal: J Gerontol A Biol Sci Med Sci Date: 2019-01-01 Impact factor: 6.053
Authors: Jacques E Rossouw; Garnet L Anderson; Ross L Prentice; Andrea Z LaCroix; Charles Kooperberg; Marcia L Stefanick; Rebecca D Jackson; Shirley A A Beresford; Barbara V Howard; Karen C Johnson; Jane Morley Kotchen; Judith Ockene Journal: JAMA Date: 2002-07-17 Impact factor: 56.272
Authors: Nina P Paynter; Raji Balasubramanian; Franco Giulianini; Dong D Wang; Lesley F Tinker; Shuba Gopal; Amy A Deik; Kevin Bullock; Kerry A Pierce; Justin Scott; Miguel A Martínez-González; Ramon Estruch; JoAnn E Manson; Nancy R Cook; Christine M Albert; Clary B Clish; Kathryn M Rexrode Journal: Circulation Date: 2018-02-20 Impact factor: 29.690
Authors: JoAnn E Manson; Rowan T Chlebowski; Marcia L Stefanick; Aaron K Aragaki; Jacques E Rossouw; Ross L Prentice; Garnet Anderson; Barbara V Howard; Cynthia A Thomson; Andrea Z LaCroix; Jean Wactawski-Wende; Rebecca D Jackson; Marian Limacher; Karen L Margolis; Sylvia Wassertheil-Smoller; Shirley A Beresford; Jane A Cauley; Charles B Eaton; Margery Gass; Judith Hsia; Karen C Johnson; Charles Kooperberg; Lewis H Kuller; Cora E Lewis; Simin Liu; Lisa W Martin; Judith K Ockene; Mary Jo O'Sullivan; Lynda H Powell; Michael S Simon; Linda Van Horn; Mara Z Vitolins; Robert B Wallace Journal: JAMA Date: 2013-10-02 Impact factor: 56.272
Authors: Marco Sciacovelli; Emanuel Gonçalves; Timothy Isaac Johnson; Vincent Roberto Zecchini; Ana Sofia Henriques da Costa; Edoardo Gaude; Alizee Vercauteren Drubbel; Sebastian Julian Theobald; Sandra Riekje Abbo; Maxine Gia Binh Tran; Vinothini Rajeeve; Simone Cardaci; Sarah Foster; Haiyang Yun; Pedro Cutillas; Anne Warren; Vincent Gnanapragasam; Eyal Gottlieb; Kristian Franze; Brian Huntly; Eamonn Richard Maher; Patrick Henry Maxwell; Julio Saez-Rodriguez; Christian Frezza Journal: Nature Date: 2016-08-31 Impact factor: 49.962
Authors: Jie Hu; Jie Yao; Shuliang Deng; Raji Balasubramanian; Monik C Jiménez; Jun Li; Xiuqing Guo; Daniel E Cruz; Yan Gao; Tianyi Huang; Oana A Zeleznik; Debby Ngo; Simin Liu; Milagros C Rosal; Rami Nassir; Nina P Paynter; Christine M Albert; Russell P Tracy; Peter Durda; Yongmei Liu; Kent D Taylor; W Craig Johnson; Qi Sun; Eric B Rimm; A Heather Eliassen; Stephen S Rich; Jerome I Rotter; Robert E Gerszten; Clary B Clish; Kathryn M Rexrode Journal: Circ Res Date: 2022-09-02 Impact factor: 23.213
Authors: Daniel Gonzalez Izundegui; Patricia E Miller; Ravi V Shah; Clary B Clish; Maura E Walker; Gary F Mitchell; Robert E Gerszten; Martin G Larson; Ramachandran S Vasan; Matthew Nayor Journal: Cardiovasc Diabetol Date: 2022-10-15 Impact factor: 8.949